Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bavituximab plus Docetaxel in 2nd-line Non-Squamous NSCLC
NCT01138163Phase 2Completed
- Sponsor
- Avid Bioservices, Inc.
- Start
- Jun 2010
- Primary completion
- Oct 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of bavituximab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Avid Bioservices, Inc. Primary endpoint: Objective Response Rate. Started Jun 2010; status: completed.
02
Drugs
bavituximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01138163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01138163.